Precision medicine researchers at UF Health are among the nation’s leading experts in studying pharmacogenomics and developing strategies to implement precision medicine into practice. Since 2011, UF Health researchers have been studying precision medicine from multiple angles and have been building an evidence-base which supports using genetic information to improve patient care. UF was among six sites chosen for the National Institutes of Health-funded Implementing GeNomics In pracTicE, or IGNITE, Network dedicated to supporting the implementation of genomics in health care and received more than $6 million in IGNITE I funding over five years. In 2018, UF was selected among five sites to lead IGNITE II and further advance the use of genomic information into medical practice.
The center focuses on improving patient outcomes through research, teaching and service focused on genetically-guided drug therapy decision making, drug discovery and drug development. Genotyping and other services are provided to the UF community and beyond.
IGNITE II is a multi-institutional research network funded by the National Institutes of Health. Five institutions, including the University of Florida, have been funded to deliver personalized health care informed by genomics through IGNITE II.
The University of Florida Clinical and Translational Science Institute has partnered with the UF College of Pharmacy to create a new annual Precision Health Initiative Pilot Grant opportunity.
All patients in this study will undergo genotyping for several genes that are associated with drug-metabolizing enzymes for drugs commonly used in supportive care regimens.